
GT Medical Technologies Acquires Radioactive Seed Assets from Perspective Therapeutics



GT Medical Technologies, Inc. (GT MedTech) announces the successful acquisition of Cesium-131 and related assets from Isoray Medical, a subsidiary of Perspective Therapeutics, Inc. This acquisition solidifies GT MedTech's position as sole manufacturer of Cesium-131 brachytherapy seeds for cancer treatments.

The completion of the acquisition is a significant investment for GT MedTech to vertically integrate the Cesium-131 manufacturing process, enhancing supply chain competencies and capabilities. This bold move underscores the company's commitment to expand adoption of GammaTile® in the U.S.

Comprised of four Cesium-131 radioactive seeds embedded within a bioresorbable collagen tile, each GammaTile is revolutionizing the treatment of brain tumors by delivering immediate targeted radiation at the time of surgery directly to the tumor bed to help eradicate residual tumor cells while minimizing impact to healthy tissue.

"With over 1300 patients benefitting from GammaTile implants and ongoing clinical trials underway, GT MedTech is dedicated to establishing GammaTile as an easier treatment option for operable brain tumor patients and a new standard of care. By starting radiation immediately at the time of tumor resection, GammaTile can prevent any delays to the needed radiation. We are excited about this acquisition and eager to utilize our expanded capabilities to propel cancer treatment forward and enhance patient outcomes." Expressed Per Langoe, CEO of GT MedTech.

"I am pleased that the Cesium-131 technology is in capable hands with the dedicated production and commercialization team at GT MedTech," said Thijs Spoor, Perspective Therapeutics' CEO. "It is important to Perspective Therapeutics that patients and clinicians continue to have access to the best possible isotope when treating cancer from the inside out."

In addition to brain brachytherapy, Cesium-131 is utilized in other forms of brachytherapy including prostate and gynecological cancers.

"This transaction positions GT MedTech as a forward-thinking company to enhance the delivery of GammaTile Therapy in the U.S. market. It bolsters our commitment to excellence in the patient journey and strengthens our partnership with clinicians who use it," said Hernan Lopez, Executive Vice President of Operations, GT MedTech.

GT MedTech welcomes the Isoray team, retaining the Cesium-131 manufacturing facility at its current location in Richland, Washington. Through enhanced integration of capabilities and ongoing investment in operational and supply chain enhancement, the company is poised to further its mission of improving the lives of patients with brain tumor.

Source & Image Credit: [GT Medical Technologies](#)

Published on : Mon, 15 Apr 2024